Presentation is loading. Please wait.

Presentation is loading. Please wait.

Minimal Clinically Important Difference (MCID) in Allergic Rhinitis: Agency for Healthcare Research and Quality or Anchor-Based Thresholds?  Eli O. Meltzer,

Published byEeva-Kaarina Saarinen Modified over 6 years ago

Similar presentations

Presentation on theme: "Minimal Clinically Important Difference (MCID) in Allergic Rhinitis: Agency for Healthcare Research and Quality or Anchor-Based Thresholds?  Eli O. Meltzer,"— Presentation transcript:

1 Minimal Clinically Important Difference (MCID) in Allergic Rhinitis: Agency for Healthcare Research and Quality or Anchor-Based Thresholds?  Eli O. Meltzer, MD, Dana Wallace, MD, Mark Dykewicz, MD, Lucy Shneyer, MA  The Journal of Allergy and Clinical Immunology: In Practice  Volume 4, Issue 4, Pages e6 (July 2016) DOI: /j.jaip Copyright © 2016 The Authors Terms and Conditions

2 APPENDIX E3 Figure 1 Search strategy adapted from AHRQ Report.E7 The number of records obtained is shown for each of 5 searches, followed by the number of records remaining after combining the appropriate searches for each of 3 queries. The number in parentheses indicates how many citations were reviewed more closely for possible inclusion in the study table. The Journal of Allergy and Clinical Immunology: In Practice 2016 4, e6DOI: ( /j.jaip ) Copyright © 2016 The Authors Terms and Conditions

Download ppt "Minimal Clinically Important Difference (MCID) in Allergic Rhinitis: Agency for Healthcare Research and Quality or Anchor-Based Thresholds?  Eli O. Meltzer,"

Similar presentations

Complementary and Alternative Medicine Use among Allergy Practices: Results of a Nationwide Survey of Allergists  Michael H. Land, MD, Julie Wang, MD 

Complementary and Alternative Medicine Use among Allergy Practices: Results of a Nationwide Survey of Allergists  Michael H. Land, MD, Julie Wang, MD 
Advances in Diagnosing Peanut Allergy

Advances in Diagnosing Peanut Allergy
Pharmacologic rationale for treating allergic and nonallergic rhinitis

Pharmacologic rationale for treating allergic and nonallergic rhinitis
Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study  Eli O. Meltzer, MD, Paul.

Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study  Eli O. Meltzer, MD, Paul.
Aleena Banerji, MD, Kimberly G. Blumenthal, MD, MSc, Kenneth H

Aleena Banerji, MD, Kimberly G. Blumenthal, MD, MSc, Kenneth H
The Natural History of Food Allergy

The Natural History of Food Allergy
Findings from an Online Survey Assessing the Burden and Management of Seasonal Allergic Rhinoconjunctivitis in US Patients  Eli O. Meltzer, MD, Judith.

Findings from an Online Survey Assessing the Burden and Management of Seasonal Allergic Rhinoconjunctivitis in US Patients  Eli O. Meltzer, MD, Judith.
Vitamin D Insufficiency and Asthma in a US Nationwide Study

Vitamin D Insufficiency and Asthma in a US Nationwide Study
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Ann-Marie M. Schoos, MD, PhD, Jacob D

Ann-Marie M. Schoos, MD, PhD, Jacob D
Luciana Kase Tanno, MD, PhD, Moises A

Luciana Kase Tanno, MD, PhD, Moises A
Chronic rhinosinusitis: Potential new use for topical sulfasalazine

Chronic rhinosinusitis: Potential new use for topical sulfasalazine
Complementary and Alternative Medicine in Allergy-Immunology: More Information is Needed  Leonard Bielory, MD  The Journal of Allergy and Clinical Immunology:

Complementary and Alternative Medicine in Allergy-Immunology: More Information is Needed  Leonard Bielory, MD  The Journal of Allergy and Clinical Immunology:
Niti Y. Chokshi, MD, Dipika Patel, MD, Carla M. Davis, MD 

Niti Y. Chokshi, MD, Dipika Patel, MD, Carla M. Davis, MD 
Dennis K. Ledford, MD, Sally Wenzel, MD 

Dennis K. Ledford, MD, Sally Wenzel, MD 
Quantitative Assessment of the Safety Benefits Associated with Increasing Clinical Peanut Thresholds Through Immunotherapy  Joseph L. Baumert, PhD, Steve.

Quantitative Assessment of the Safety Benefits Associated with Increasing Clinical Peanut Thresholds Through Immunotherapy  Joseph L. Baumert, PhD, Steve.
Jennie Gane, MBChB (Hons), MSc, Roger Buckley, BM BCh, MA, FRCS 

Jennie Gane, MBChB (Hons), MSc, Roger Buckley, BM BCh, MA, FRCS 
Dana V. Wallace, MD, Mark S. Dykewicz, MD, David I

Dana V. Wallace, MD, Mark S. Dykewicz, MD, David I
Desensitization to Chemotherapeutic Agents

Desensitization to Chemotherapeutic Agents
Intramuscular Versus Intravenous Immunoglobulin Replacement Therapy and Measurement of Immunoglobulin Levels During Immunoglobulin Replacement Therapy 

Intramuscular Versus Intravenous Immunoglobulin Replacement Therapy and Measurement of Immunoglobulin Levels During Immunoglobulin Replacement Therapy 

Similar presentations

Ads by Google